Profile

Jun Li, M.D & Ph.D,

Professor

Vice Director

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases

The First Affiliated Hospital, School of Medicine

Zhejiang University

79 Qingchun Rd. 6A-15F

Hangzhou, China. 310003

ResearcherID: E-4744-2012

 

Jun Li, MD & Ph.D is a “Qiushi” professor and vice director in State Key Laboratory for Diagnosis and Treatment of Infectious Diseases at The First Affiliated Hospital, College of Medicine, Zhejiang University. Dr. Li specializes in regenerative medicine for treatment of hepatic failure. Dr. Li is also an Editorial Board Member of Sci Rep and Hepatoma Res.

 

Dr. Li’s primary areas of research involve the bioartificial liver support system and liver tissue engineering. He spent three years working at the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases at The First Affiliated Hospital, College of Medicine, Zhejiang University in China and received his Ph.D degree in 2003, during which time he established an immortalized human hepatocyte line HepLL as a cell source of bioartificial liver support system. Dr. Li also spent two and half years (2006-2008) as a PostDoctoral Fellow in Cedars-Sinai Medical Center in USA. His research focuses on the regenerative medicine for treatment of hepatic failure. The main achievements: (1) He founded that bone marrow mesenchymal stem cell (BMSC) is an important source for liver regeneration and restoration when liver damaged in FHF. He has also demonstrated that human BMSCs transplantation can prevent death from FHF in pig animal model and an important cytokine, Delta-like ligand 4 may participate in restoring the damaged liver in FHF. These results delineated an integrated model of the multifaceted interactions between stem cells and recipients, which may open a new avenue to the discovery of single molecule-based therapeutics that simulate stem cell actions. (2) He has clarified the distinct clinicopathological characteristics of patients with hepatitis B-related ACLF (HBV-ACLF) different from those of alcoholic liver disease-related ACLF in Western populations and developed new evidence-based diagnostic criteria (Chinese Group on the Study of Severe Hepatitis B-ACLF, COSSH-ACLF) and a prognostic scoring system for HBV-ACLF patients with a large, prospective, multicenter study. The new COSSH-ACLF bridges the gap in the CLIF-ACLF criteria proposed by the Chronic Liver Failure (CLIF) Consortium Acute-On-Chronic Liver Failure in Cirrhosis (CANONIC) of European Association for the Study of the Liver (EASL) for an HBV-ACLF diagnosis. Compared with the EASL-ACLF, the COSSH-ACLF identified approximately 20% more patients with ACLF who can receive earlier clinically intensive management. (3) He has demonstrated that PLGA scaffold could significantly improve growth and functions of primary human hepatocytes, and increase the ability of differentiation of BMSCs into mature hepatocytes, which indicated that this material can possibly be used as a bioscaffold for liver tissue engineering in future clinical therapeutic applications. Moreover, His team has established a new platform for restoring a liver-like organ in vitro using the decellularized liver scaffolds.

 

He has received >10 national key grants including the National Natural Science Foundation of China and “863 plan”. He has written articles for numerous peer-reviewed publications, including the Gut, Hepatology and Biomaterials.



Research work

Regenerative medicine for treatment of hepatic failure

Contact

Phone:86-571-87236425
E-mail:lijun2009@zju.edu.cn